SFJ Pharmaceuticals has formed its second collaborative development agreement with Pfizer, this time to conduct a Phase III trial to evaluate Pfizer’s pan-Her (pan-human epidermal growth factor receptor) inhibitor dacomitinib (PF-00299804) as a first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with activating EGFR (epidermal growth factor receptor) mutations. The NSCLC market continues to move towards molecular-targeted therapies used alongside companion diagnostics to guide treatment decisions.